

AMENDMENT

Replace **claim 49** with the following claim:

49. (amended) The pharmaceutical composition according to claim 40, in an intravenously injectable form.

REMARKS

Claims 26-51 are currently pending and being examined.

Applicants enclose a translation into the English language of French priority document FR 96/11186.

Claim 49 is amended to correct the error noted at page 5 of Paper No. 5. No new matter enters by this amendment. A marked-up comparison of amended claim 49 to the previous claim 49 appears as Appendix 1, in compliance with 37 C.F.R. § 1.121.

Rejection under 35 U.S.C. § 112, First Paragraph

Claims 26-53, 37-42, 44, 45, 49, 50, and 51 stand rejected under 35 U.S.C. § 112, first paragraph, as the specification allegedly fails to enable one of skill in the art to make and use the claimed invention. Applicants respectfully disagree.

Applicants note that the specification includes several examples showing how to make and use the compositions, expression systems, expression cassettes, and vectors of the claimed invention in an appropriate transgenic mouse model. That recombinant adenoviral vectors are shown in Examples 5-10 does not in any way indicate that other compositions comprising expression cassettes cannot be selected and used. In fact, Example 2.1 clearly shows that plasmid vectors, for example, can be selected. Thus, applicants have clearly stated that the application enables the claimed invention. It is therefore the PTO's burden to establish that